CMPS
COMPASS Pathways Plc
$6.57
-$0.04(-0.61%)
34
Overall
--
Value
45
Tech
23
Quality
Market Cap
$671.16M
Volume
557.53K
52W Range
$2.25 - $8.20
Target Price
$17.27
Company Overview
| Mkt Cap | $671.16M | Price | $6.57 |
| Volume | 557.53K | Change | -0.61% |
| P/E Ratio | -4.3 | Open | $6.62 |
| Revenue | -- | Prev Close | $6.61 |
| Net Income | $-155.1M | 52W Range | $2.25 - $8.20 |
| Div Yield | N/A | Target | $17.27 |
| Overall | 34 | Value | -- |
| Quality | 23 | Technical | 45 |
No chart data available
About COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and COMPASS Pathways (CMPS)
Brian Anderson•5 days ago
3 ‘Strong Buy’ Stocks to Buy Today,1/9/2026, According to Top Analysts
Shalu Saraf•25 days ago
Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
COMPASS Pathways expands Hercules loan facility for runway
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CMPS | $6.57 | -0.6% | 557.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |